EBITDA: Income before interest, taxes, depreciation and amortization.
Actinium Pharmaceuticals, Inc. (ATNM) had EBITDA of $-5.68M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-5.52M |
|
-- |
|
-- |
|
$5.90M |
|
$-5.90M |
|
$0.38M |
|
$-5.52M |
|
$-5.52M |
|
$-5.52M |
|
$-5.52M |
|
$-5.52M |
|
$-5.52M |
|
$-5.90M |
|
|
EBITDA |
$-5.68M |
31.24M |
|
31.24M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$43.26M |
|
$0.27M |
|
$2.18M |
|
$45.44M |
|
$7.35M |
|
-- |
|
$35.78M |
|
$43.13M |
|
$2.30M |
|
$2.30M |
|
$2.30M |
|
31.38M |
|
| Cash Flow Statement Financials | |
$-5.87M |
|
$-0.00M |
|
$-0.00M |
|
$48.33M |
|
$42.47M |
|
$-5.86M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.89 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-239.67% |
|
-239.67% |
|
-12.15% |
|
-239.67% |
|
$0.07 |
|
$-0.19 |
|
$-0.19 |
|